Category Archives: Deals
By Pharm Exec | Published: June 13, 2014
The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
By Guest Blogger | Published: June 13, 2014
By Cliff Kalb. The major pressures hindering pharmaceutical industry success have not changed—payer constraints on drug costs, R&D productivity, an increasingly risk-averse regulatory climate, generic encroachment, and negative public perceptions linked to reputation. Looking at the latest rendition of the Pharma 50, prescription drug revenue rankings for the top 10 major global players in 2013 […]
By Pharm Exec | Published: June 3, 2014
Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
By Pharm Exec | Published: May 13, 2014
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
By Guest Blogger | Published: May 5, 2014
As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again, I suspect that we will shortly be entering a transition where the tone will become a bit more hostile. Pfizer has been down this road before, when the deal to buy Warner Lambert in 2000 for $90 billion turned somewhat hostile. At […]